Sublingual immunotherapy in allergic rhinitis
10.5415/apallergy.2011.1.3.123
- Author:
Doo Hee HAN
1
;
Chae Seo RHEE
Author Information
1. Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul 110-799, Korea. csrhee@snu.ac.kr
- Publication Type:Review
- Keywords:
Immunotherapy;
Sublingual administration;
Rhinitis
- MeSH:
Administration, Sublingual;
Asthma;
Compliance;
Desensitization, Immunologic;
Drug Therapy;
Immunotherapy;
Korea;
Nasal Surgical Procedures;
Rhinitis;
Rhinitis, Allergic;
Sublingual Immunotherapy
- From:
Asia Pacific Allergy
2011;1(3):123-129
- CountryRepublic of Korea
- Language:English
-
Abstract:
Current treatment options for allergic rhinitis (AR) include allergen avoidance and environmental control, pharmacotherapy, nasal surgery and immunotherapy. Among these, immunotherapy is the only therapeutic option that modifies fundamental immunologic mechanism by inducing desensitization. Specific allergen immunotherapy has been used for 1 century since 1911 and subcutaneous immunotherapy (SCIT) has been demonstrated to be effective in asthma and AR. However, SCIT has several disadvantages such as inconvenience, invasiveness and potentially severe systemic reactions. Thus, sublingual immunotherapy (SLIT) has recently received much attention around the world as a treatment for AR and is now widely used to replace the subcutaneous route. SLIT has recently been introduced in Korea and is now available for AR treatment in the Asia-Pacific region. This review offers better understanding of SLIT for AR by summarizing published articles and our previous works regarding proposed mechanisms, indication and efficacy, safety and adverse events, and compliance.
